$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
西妥昔单抗属于什么药,几天起效?
2025-10-19 11:44:20
Check Details
西妥昔单抗一般用几个疗程,用多久可停药?
2025-10-19 11:44:20
Check Details
西妥昔单抗几天起效,会让肿瘤消失吗?
2025-10-19 11:44:20
Check Details
西妥昔单抗耐药的表现是怎样的,耐药后怎么处理?
2025-10-19 11:44:20
Check Details
瑞戈非尼吃了多久起效,饭后多久可以吃?
2025-10-19 11:44:20
Check Details
瑞戈非尼禁忌是什么,需要注意什么事项?
2025-10-19 11:44:20
Check Details
瑞戈非尼2022年医保报销条件是什么,哪里能买到?
2025-10-19 11:44:20
Check Details
瑞戈非尼一定要早上吃吗,用法用量是怎样的?
2025-10-19 11:44:20
Check Details
西妥昔单抗2022报销条件,河南哪里能买到?
2025-10-19 11:44:20
Check Details
比美替尼作用与价格
2025-10-19 11:44:20
Check Details
西妥昔单抗副作用有哪些,副作用多久消失?
2025-10-19 11:44:20
Check Details
长期服用瑞格非尼会出现什么副作用?
2025-10-19 11:44:20
Check Details
1
2
...
7710
7711
7712
7713
7714
7715
7716
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
2
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
3
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
4
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
5
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
6
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
7
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
8
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
9
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
12
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance